A Phase II Study of Docetaxel and Epirubicin in Advanced Adult Soft Tissue Sarcomas (STS)

Purpose: The aim of this study was to determine the efficacy and safety of docetaxel plus epirubicin combination as first-line chemotherapy in patients with locally advanced and/or metastatic adult STS. Patients and Methods: Eighteen patients were treated with epirubicin 30 mg/m2 on days 1 to 3 and docetaxel 100 mg/m2 on day 1 every 3 weeks. Results: Fifteen out of 18 patients (83.4%) were assessable for response. No complete response was recorded. Three (20%) patients achieved PR, 3 had SD and 9 PD. The overall median survival was 14 months (range, 3–48 months) and the median time to disease progression was 4 months (range, 2–45 months). Grade ≥ 3 neutropenia occurred in 88% and neutropenic fever in 27.8% of patients. Other toxicities were mild. No treatment related deaths occurred. Discussion: Docetaxel plus epirubicin combination achieved low response rate with severe myelotoxicity in patients with advanced STS.

[1]  M. Karamouzis,et al.  Adriamycin and Cis-Platinum as First-Line Treatment in Unresectable Locally Advanced or Metastatic Adult Soft-Tissue Sarcomas , 2004, American journal of clinical oncology.

[2]  Shreyaskumar R Patel.  Recent advances in systemic therapy of soft tissue sarcomas , 2003, Expert review of anticancer therapy.

[3]  E. Venkatraman,et al.  Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  L. Cattel,et al.  Clinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer , 2001, Breast Cancer Research and Treatment.

[5]  A. Riva,et al.  Taxane/anthracycline combinations: setting a new standard in breast cancer? , 2001, The oncologist.

[6]  P. Watkins,et al.  The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  Earhart Rh.  Docetaxel (Taxotere): preclinical and general clinical information. , 1999, Seminars in oncology.

[8]  O. S. Nielsen,et al.  High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group. , 1998, British Journal of Cancer.

[9]  B. Dörken,et al.  Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  K. Bélanger,et al.  A Phase II Study of Docetaxel in Chemotherapy-Naïve Patients With Recurrent or Metastatic Adult Soft Tissue Sarcoma , 1998, Sarcoma.

[11]  J. Edmonson,et al.  Phase II study of docetaxel in advanced soft tissue sarcomas. , 1996, American journal of clinical oncology.

[12]  J. Verweij,et al.  Phase II study with Docetaxel (Taxotere®) in advanced soft tissue sarcomas of the adult , 1994 .

[13]  N. Habboubi,et al.  Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. , 1993, Cancer treatment reviews.

[14]  D. Coit,et al.  Lymph Node Metastasis From Soft Tissue Sarcoma in Adults Analysis of Data From a Prospective Database of 1772 Sarcoma Patients , 1993, Annals of surgery.

[15]  A. Elias,et al.  Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Benjamin,et al.  Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas. , 1980, Cancer treatment reports.

[17]  B Sundell,et al.  Soft-tissue sarcomas. , 1979, British medical journal.

[18]  S. Green,et al.  Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas , 2004, Cancer Chemotherapy and Pharmacology.

[19]  C. Neumaier,et al.  Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a phase II study. , 1999, European journal of cancer.

[20]  M. van Glabbeke,et al.  Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Earhart.  Docetaxel (Taxotere): preclinical and general clinical information. , 1999, Seminars in oncology.

[22]  F. Collin,et al.  Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.